1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Arena Sees Phase III Path For Etrasimod After Atopic Dermatitis Miss

Analysts Agreed The S1P Receptor Modulator Should Advance

 
• By Mandy Jackson

Arena said its S1P receptor modulator missed the primary endpoint in a Phase IIb trial but data from patients with uninterrupted treatment justify moving etrasimod into a pivotal program.

Pathway in the garden outdoor, forward stepping stones or pebbled in the grass lawn.
Arena identified a path forward for etrasimod in atopic dermatitis • Source: Shutterstock

Arena Pharmaceuticals, Inc.’s sphingosine 1-phosphate (S1P) receptor modulator etrasimod did not meet the primary endpoint in the Phase IIb ADVISE clinical trial but the company said its review of data from moderate-to-severe atopic dermatitis patients with uninterrupted courses of treatment show a significant benefit that justifies moving the drug into Phase III testing in the skin disease.

San Diego-based Arena discussed top-line data from ADVISE during a conference call after the stock market closed on 9 November,...

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.